Jun 23, 2014
Akorn Divests ECR Pharmaceuticals to Valeant
Akorn has sold its subsidiary, ECR Pharmaceuticals, to Valeant Pharmaceuticals for $41 million in cash and assumption of certain liabilities.
FTC Approves Final Order Settling Charges That Akorn Enterprises' Acquisition of Hi-Tech Pharmacal Was Anticompetitive
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Akorn Enterprises' $640 million acquisition of Hi-Tech Pharmacal, Inc. was anticompetitive and would lead to higher prices for consumers in several current and future generic drug markets.
Intellectual Property Infringements and Supply Chain Vulnerabilities...
Amid uncertainties around patent protection and lawmakers putting an indefinite hold on patent reform legislation, life sciences companies are increasingly pointing to intellectual property infringement as a threat.